Clinical Report: "Plug-and-Play" CAR T Platform Enables Post-Infusion Retargeting

Overview

The modular CAR T-cell platform, termed meCAR, allows for post-infusion modifications of engineered immune cells. Preclinical studies demonstrate that this platform can improve T-cell expansion and tumor targeting.

Background

Chimeric antigen receptor (CAR) T-cell therapy has shown significant promise in treating various malignancies, particularly B-cell cancers. However, conventional CAR T cells have limitations due to their fixed specificity, which can hinder effectiveness against heterogeneous tumors, where cancer cells may express different antigens or lose the targeted antigen during treatment.

Data Highlights

Preclinical studies indicate that meCAR T cells demonstrated comparable tumor-cell killing to conventional CAR T cells, and using an interleukin-15 superagonist adaptor increased T-cell expansion and reduced tumor burden in mouse models.

Key Findings

• The meCAR platform allows for the binding of external protein adaptors to modify CAR T-cell behavior post-infusion.
• In preclinical experiments, meCAR T cells demonstrated comparable tumor-cell killing to conventional CAR T cells.
• Using an interleukin-15 superagonist adaptor, meCAR T cells showed increased expansion and reduced tumor burden in mouse models.
• HER2-targeting meCAR T cells were successfully redirected to attack CD20-positive cancer cells using meditope-linked antibodies.
• Excessive concentrations of adaptors may reduce the effectiveness of CAR T-cell interactions, indicating the need for careful dosing.

Clinical Implications

The meCAR platform introduces a method for modifying CAR T-cell behavior post-infusion, which may require careful consideration of adaptor dosing and pharmacokinetics.

Conclusion

The development of the meCAR platform represents a potential advancement in CAR T-cell therapy.

Related Resources & Content

1. City of Hope, Cancer Immunology Research, 2023 -- "Plug-and-Play CAR T Platform Enables Post-Infusion Retargeting"
2. Blood Cancer Journal — Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts
3. The ASCO Post — New Data on ALK Inhibitors and CAR T-Cell Therapies
4. the medicine maker — Making CAR T Truly Off the Shelf
5. the medicine maker — CRISPR Enables In Vivo CAR T Cell Production
6. Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts
7. New Data on ALK Inhibitors and CAR T-Cell Therapies
8. Making CAR T Truly Off the Shelf
9. ASTCT Consensus Grading for Toxicities after Immune Effector Cell Therapy
10. FDA approves lisocabtagene maraleucel for relapsed or refractory marginal zone lymphoma
11. The Current Landscape of Modular CAR T Cells - PMC